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Research Paper

The role of p53 in the trafficking of copper-64 to tumor cell nuclei
Martin Eiblmaier, Laura A. Meyer and Carolyn J. Anderson*
Mallinckrodt Institute of Radiology; Washington University School of Medicine; Saint Louis, Missouri USA

Abbreviations: BSA, bovine serum albumin; CB-TE2A , 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane; DOTA,
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; DTPA, diethylenetriaminepentaacetic acid; EDTA, ethylene diamine tetraacetic
acid; EGFR, epidermal growth factor receptor; FITC, fluorescein isothiocyanate; mAb, monoclonal antibody; PET, positron emission
tomography; SDS, sodium dodecyl sulfate; SPECT, single photon emitted computed tomography; SSTr2, somatostatin receptor subtype
2; TETA, 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid; TLC, thin-layer chromatography; Y3-TATE, tyrosine-3 octreotate;
WT, wild type
Key words: copper-64, nuclear localization, targeted radiotherapy, tumor cell nuclei, p53, copper chaperone

Copper‑64 (T1/2 = 12.7 h; b+: 17.8%, b‑: 41%) has applica‑
tions in both positron emission tomography (PET) imaging and
targeted radiotherapy of cancer. Copper‑64 radiopharmaceuticals
have shown tumor growth inhibition with a relatively low radiation
dose in animal models; however, the mechanism of cytotoxicity has
not been fully elucidated. Here, we report an investigation on the
potential role of the tumor suppressor protein p53 in trafficking
64Cu to tumor cell nuclei. Two EGFR expressing human colorectal
cell lines (HCT 116 +/+ and HCT 116 ‑/‑) that are positive or
negative for p53 expression respectively, were used to compare
internalization and nuclear localization of [64Cu]copper acetate
and of 64Cu‑DOTA‑cetuximab, a monoclonal anti‑EGFR antibody.
[64Cu]copper acetate uptake into cells was similar between the
two cell lines during a 24 h time course. In contrast, the uptake
of [64Cu]copper acetate in the nuclei of HCT 116 +/+ cells was
significantly higher than in HCT 116 ‑/‑ cells (p < 0.0001) at 24
h. There was no difference in receptor binding, receptor‑mediated
internalization, and efflux of 64Cu‑DOTA‑cetuximab between
the two HCT 116 cells lines. However, nuclear localization of
64Cu‑DOTA‑cetuximab showed increased uptake in the nuclei of
HCT 116 +/+ cells as early as 4 h. These data demonstrate that
64Cu is delivered to tumor cell nuclei in a p53 positive cell line in
significantly greater amounts than in p53 negative cells by both
non-specific and receptor‑mediated uptake mechanisms.

Introduction
There has been increasing interest in the use of copper radio‑
pharmaceuticals for PET imaging and/or targeted radiotherapy of
cancer. Copper‑64 (T1/2 = 12.7 h; b+: 0.655 MeV; 17.8%; b‑: 0.573
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MeV; 41%) emits both b+ and b‑ radiation for PET and therapy
applications, while 67Cu (T1/2 = 62 h; 100% b‑: 0.576 MeV max) is
a b‑ emitter that has shown success in radioimmunotherapy of nonHodgkin’s lymphoma in tumor‑bearing mice1‑3 and in humans.4,5
We previously observed that 64Cu‑labeled tumor‑targeting agents
showed enhanced therapeutic efficacy of an internalizing 64Cu‑labeled
anti‑colorectal carcinoma mAb, 64Cu‑labeled 1A3, in a tumor‑bearing
hamster model compared to 90Y‑ or 131I‑labeled mAbs in the same
animal model.6,7 We also evaluated the 64Cu‑labeled somatostatin
analogs octreotide and Y3‑TATE as therapeutic agents, and although
we did not observe complete tumor remissions, we did see tumor
growth inhibition at relatively low radiation doses to the tumors
(465‑600 cGy).8,9
Particularly in the area of receptor‑targeted therapy agents,10,11
the intracellular fate of the radiopharmaceuticals following binding
to cell surface receptors has been a topic of interest.12,13 It was
previously demonstrated that 111In from 111In‑DTPA‑octreotide
(Octreoscan®), an imaging agent clinically approved for somatostatin‑
receptor positive tumors in the United States and Europe, showed
uptake in tumor cell nuclei.12 This suggests a possible mechanism for
the therapeutic efficacy of this Auger electron‑emitting radiopharma‑
ceutical. We demonstrated that 64Cu from 64Cu‑TETA‑octreotide
was significantly localized in the nuclei of AR42J rat pancreatic tumor
cells in cell culture, whereas 111In from 111In‑DTPA‑octreotide was
localized to tumor cell nuclei in much smaller amounts.14 Although
64Cu only emits 2 Auger electrons per decay, it has been reported
that the recoil energy from the transmutation of this radionuclide
in the vicinity of DNA can cause lethal damage to the cell.15 These
data suggested that delivery of 64Cu to the cell nuclei may enhance
the therapeutic effect of beta‑emitting, tumor targeting copper radio‑
pharmaceuticals.
Because copper can readily form oxygen radicals, free copper
essentially does not exist in vivo.16 Several chaperones have been
identified that transport copper to various organelles in mammalian
cells (for a review on this subject, see ref. 17). Copper is trans‑
ported into the cell via hCtr1 (human copper transporter). Several
chaperones serve to traffic copper between cellular compartments.
Cox17 carries copper to the mitochondria for incorporation into
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cytochrome c. Copper can also be incorporated into nascent Cu/Zn
SOD via the copper chaperone CCS. The Wilson disease P‑type
ATPase receives copper from HAH1 in the trans‑golgi‑network, where
copper binds to ceruloplasmin during synthesis. Metallothionein is
thought to play a role as a copper storage pool within the cell.18 To
date, no chaperones have been identified that traffic copper to the
cell nucleus. There are proteins common in tumors and other tissues
that may play a role in the transport of copper to the nucleus. The
tumor suppressor protein p53 is a critical cellular mediator of the
response to oxidative stress and genotoxic damage. Upon activation,
p53 accumulates in the nucleus where it transcriptionally activates
the expression of a number of proteins. There is in vitro evidence that
copper may displace zinc in the p53 structure.19
In addition to the possibility that 64Cu might bind to p53 itself,
there is also evidence that p53 facilitates the transport of other
copper‑based proteins to the nuclei of tumor cells. Azurin is a cupre‑
doxin protein secreted by Pseudomonas aeruginosa. It has been shown
to have cytotoxic effects on J774 macrophages and human breast
cancer cells.20,21 The induction of apoptosis by azurin is independent
of its redox activity and involves complex formation with p53 and
translocation to the nucleus.22‑24
Here we report on the transport of 64Cu to the nuclei of
HCT116 cells lines that are either p53 WT or p53 negative (herein
referred to as HCT 116 +/+ and HCT 116 ‑/‑). We evaluated
[64Cu]copper acetate, which will bind to proteins in serum and be
taken up by cells via the hCtr1 transporter, as well as the EGFR
antibody 64Cu‑DOTA‑cetuximab, which will be delivered to the
EGFR‑positive HCT 116 cell lines by a receptor‑mediated pathway.
Cetuximab was the first monoclonal antibody targeted against the
ligand‑binding site of EGFR to be approved by the FDA for the
treatment of patients with EGFR‑expressing, metastatic colorectal
carcinoma.25‑27 We demonstrate a potential pathway for the traf‑
ficking of copper (in the form of 64Cu) to the nuclei of tumor cells
via the tumor suppressor protein, p53.

Results
Internalization and nuclear uptake of [64Cu]copper acetate.
HCT 116+/+ and HCT 116‑/‑ cells were incubated with [64Cu]copper
acetate over a 24 h time course to measure internalization. 64Cu
accumulated in both lines over time and reached approximately
20% ID/mg at 24 h. Minimal difference was observed between the
two cell lines (Fig. 1A). p53 status thus had no apparent influence
on transport of 64Cu via the hCtr1 transporter. The difference in
nuclear uptake of 64Cu, however, was quite significant (Fig. 1B).
At the end of the 24 h time course, 64Cu accumulation in the
nuclei was two‑fold higher in HCT 116 +/+ cells compared HCT
116 ‑/‑ cells (8.26 ± 0.13 vs. 4.05 ± 0.07% ID/mg cellular protein, n = 3,
p < 0.0001). Even though uptake of 64Cu from [64Cu]copper acetate
was not influenced by p53 status, transport of this radiometal to the
nucleus was significantly higher in the p53 expressing cell line.
To test for the integrity of the HCT 116 cell lines utilized
in this study, which have been passaged for several decades, and
to ensure the absence of clonal artifacts, HCT 116+/+ cells were
treated with p53 siRNA (short interfering RNA, silencing RNA)
to downregulate p53 mRNA and p53 protein. After three days,
these cells were exposed to 25 mCi of [64Cu]copper acetate, and
cell nuclei were isolated and measured for 64Cu activity. Nuclear
uptake was significantly lower in HCT 116+/+ cells treated with
64

p53 siRNA (0.126 ± 0.008% ID/mg, n = 3) compared to untreated
HCT 116 +/+ cells (0.252 ± 0.003% ID/mg, n = 2, p < 0.01). There
was no statistical significance between down‑regulated HCT 116+/+
cells and HCT 116‑/‑ cells (0.165 ± 0.033% ID/mg, n = 2, p = 0.23).
Thus, downregulation of p53 mRNA and protein in HCT 116+/+
cells led to nuclear localization of 64Cu more similar in quantity to
HCT 116‑/‑ cells than to HCT 116+/+ cells. This control experiment
reduces the probability that clonal artifacts were responsible for the
64Cu nuclear uptake patterns observed in the two HCT 116 clones.
Synthesis and receptor binding of 64Cu‑DOTA‑cetuximab.
Next, experiments were performed to determine whether this
difference would be observed when 64Cu enters the cells via a recep‑
tor‑mediated pathway. HCT 116 cells express EGFR, and we chose
64Cu‑DOTA‑cetuximab as a vector for bringing 64Cu into HCT
116 cells. Cetuximab is a humanized anti‑EGFR monoclonal antibody
and has been approved by the FDA for treatment of EGFR‑positive
metastatic colorectal cancer and advanced head‑and‑neck cancer.
DOTA is a well‑characterized chelator for copper, and it is
known that 64Cu can dissociate from the 64Cu‑DOTA complex
in vivo.32 64Cu‑DOTA‑cetuximab was produced with a specific
activity of 10 –15 mCi/mg [0.37–0.56 MBq/mg; 1.5–2.3 nCi/fmol
(560–860 Bq/fmol)]. Initial radiochemical purity ranged from
75–100%. For yields < 95%, 64Cu‑DOTA‑cetuximab was chal‑
lenged with 5 ml of 10 mM EDTA to complex free 64Cu.
64Cu‑DOTA‑cetuximab was then isolated with a miniature size
exclusion column, resulting in final radiochemical purities ranging
from 98 ‑ 100%. Saturation receptor binding experiments with
64Cu‑DOTA‑cetuximab and isolated HCT 116 +/+ and HCT 116
‑/‑ cell membranes showed that there was no significant difference
in the binding characteristics between the two cell lines (Fig. 2).
The dissociation constant (Kd) was 0.95 ± 0.26 nM for HCT 116+/+
cells and 1.13 ± 0.22 nM for HCT 116‑/‑ cells. These values are
comparable to dissociation constants reported for unmodified cetux‑
imab, which range from 0.15–1.2 nM.33,34 Maximum EGF receptor
densities (Bmax) were very similar as well: 1,950 ± 180 fmol/mg for
HCT 116+/+ cells, and 2,180 ± 150 fmol/mg for HCT 116‑/‑ cells.
It was important to demonstrate that EGF receptor numbers were
comparable for both cell lines and were not dependent on their p53
status in order to exclude the possibility that a difference in receptor
numbers would confound the results of internalization, nuclear
uptake, and efflux studies with 64Cu‑DOTA‑cetuximab.
Internalization and nuclear uptake of 64Cu‑DOTA‑cetuximab.
These experiments were performed in the same manner as
described for [64Cu]copper acetate. Figure 3A shows the uptake
of 64Cu‑DOTA‑cetuximab into both HCT 116 cell lines. As was
the case with [64Cu]copper acetate, internalization was similar in
both lines. However, uptake did not increase between the 4 h and
24 h time point. It is possible that the receptor‑mediated uptake of
64Cu‑DOTA‑cetuximab was saturated at 4 h, whereas non-specific
uptake of [64Cu]copper acetate increased over the 24 h time course.
At 24 h the total amount of internalized 64Cu‑DOTA‑cetuximab was
43.7 ± 1.3% ID for HCT 116+/+ cells vs. 42.2 ± 3.3% ID for HCT
116‑/‑ cells (P = 0.68, N = 6, data not shown). As expected from similar
Kd and Bmax values for the interaction of 64Cu‑DOTA‑cetuximab
and the EGF receptor on the two HCT 116 cell lines, a difference
in receptor‑mediated endocytosis of 64Cu‑DOTA‑cetuximab could
not be observed.
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dismutase.36 Copper also exists in the cell nucleus and
can interact with DNA; however, it is not known how
copper enters the nucleus or which proteins may assist
in its transport.
In the case of 64Cu, nuclear localization may have
an additional effect on targeted radiotherapy of cancer.
If transported to the nucleus, 64Cu from radiophar‑
maceuticals may have improved tumor cell killing
properties in tumors, in part due to the delivery of
a higher radiation dose to nuclear DNA. This extra
dose comes from two Auger electrons with energies
of 6.5 keV (22.5%) and 840 eV (57.7%), which are
emitted by 64Cu. According to the MIRD database,37
the range for the 6.5 keV electron is less than 1.5 mm
Figure 1. Internalization (A) and nuclear localization (B) of [64Cu]copper acetate in HCT in soft tissues, while the range for the 840 eV electron
116 cell lines positive (£) and negative (p) for p53 (N = 3) in %ID/mg.
is only 0.05 mm. The diameter of HCT 116 tumor
cell nuclei was determined to be 12–13 mm, therefore,
nuclear localization is clearly necessary to bring tumor
When isolated nuclei were measured for 64Cu activity after incu‑ cell DNA in range of these Auger electrons. Another potential mode
bation with 64Cu‑DOTA‑cetuximab (Fig. 3B), numbers were higher of cell killing is caused by the recoil energy associated with the trans‑
in HCT 116+/+ cells compared to HCT 116‑/‑ cells (0.56 ± 0.05% mutation of 64Cu nuclei to stable 64Ni (b+ decay) or 64Zn (b‑ decay).
vs. 0.36 ± 0.03% of internalized activity/mg cellular protein at Apelgot and colleagues proposed that this mode of cell killing may
24 h, P < 0.001, N = 6). Those values correspond to 10.3 ± 1.0% be important if the decays occur within the DNA molecule itself, as
and 7.0 ± 0.5% of internalized 64Cu‑DOTA‑cetuximab (P = 0.01, N DNA is highly sensitive to changes in its structure.15
We previously demonstrated that 64Cu localized to the nuclei
= 6, data not shown). In contrast to the analogous experiment with
64
[ Cu]copper acetate, when a significant difference had not been from 64Cu‑TETA‑octreotide in AR42J rat pancreatic tumor cells,38
seen at early time points, more 64Cu from 64Cu‑DOTA‑cetuximab and from 64Cu‑TETA‑Y3‑TATE in A427‑7 human non-small cell
appeared in the nuclei of HCT 116+/+ cells as early as 1 h, with the lung carcinoma cells.39 64Cu‑CB‑TE2A‑Y3‑TATE is a very stable
difference being statistically significant at 4 h (0.75 ± 0.09% vs. copper complex, and no nuclear accumulation has been observed
with this somatostatin analogue over 24 h.39 This finding supports
0.47 ± 0.05% of internalized activity/mg, p = 0.02, n = 6).
64
64
Efflux of Cu‑DOTA‑cetuximab. We hypothesize that Cu the hypothesis that 64Cu must dissociate from its chelator before
dissociates from 64Cu‑DOTA‑cetuximab and is complexed by a entering the nucleus. Given the lack of free copper ions in living
different protein before entering the cell nucleus. It is possible that systems, a yet unidentified binding partner involved in copper traf‑
this new complex also translocates to other cell compartments or ficking to the nucleus almost certainly exists.
We present research indicating that the tumor suppressor protein
leaves the tumor cell. To rule out that the observed difference in
nuclear uptake between the two HCT 116 cell lines resulted from p53 is directly or indirectly involved in the process of copper
a variation in release of 64Cu into the medium, 64Cu efflux was transport to tumor cell nuclei. 64Cu administered as [64Cu]copper
monitored for 20 h after an uptake period of 4 h. Figure 4 shows acetate and 64Cu‑DOTA‑cetuximab entered the nuclei of HCT
the efflux profiles of both cell lines. Both cell lines retained compa‑ 116+/+ cells, which express p53, in significantly greater amounts
rable amounts of 64Cu from internalized 64Cu‑DOTA‑cetuximab than was the case with HCT 116‑/‑ cells (Figs. 1B and 3B), which
throughout the time course, with the exception of increased efflux lack both p53 alleles. In the case of [64Cu]copper acetate, the
of 64Cu from HCT 116‑/‑ cells at 4 h. This time point may be an metal is transported into the tumor cells via the hCtr1 transporter.
outlier, and the overall profiles suggest that the difference in 64Cu 64Cu‑DOTA‑cetuximab, a monoclonal chimeric antibody against
efflux between HCT 116 cell lines is minimal.
the EGF receptor, enters the cell by receptor‑mediated endocytosis.
Different uptake mechanisms may account for the observation that
Discussion
the uptake of 64Cu‑DOTA‑cetuximab into HCT 116+/+ nuclei was
Copper is one of the most important trace metals in humans, significantly increased after 4 h of exposure to the radiopharma‑
being surpassed in abundance only by iron and zinc.35 Therefore, ceutical (Fig. 3B), whereas a significant increase of [64Cu]copper
mechanisms for copper uptake, transport and excretion exist within acetate uptake occurred only at 24 h (Fig. 1B). Control experi‑
all living cells. Molecular imaging and targeted radiotherapy can ments showed that uptake of [64Cu]copper acetate (Fig. 1A) and
take advantage of these mechanisms, e.g., by developing strategies 64Cu‑DOTA‑cetuximab (Fig. 3A), as well as receptor binding
to deliver radioactive isotopes like 64Cu or 67Cu to target cells. Due (Fig. 2) and efflux of 64Cu‑DOTA‑cetuximab (Fig. 4) are not
to its cytotoxicity, however, copper exists in biological systems only significantly different between p53 positive and negative cell lines.
in a chelated species, bound by small molecules or proteins. Many Thus, increased trafficking of 64Cu into HCT 116+/+ cell lines is not
of these copper binding proteins have been identified, such as the confounded by increased uptake or reduced efflux.
p53 protein is maintained at very low levels in the absence of
ubiquitous copper transporter hCtr1, or the metallochaperone CCS,
which delivers the metal to the copper redox enzyme superoxide cellular stress.40 It can be activated by many conditions such as
www.landesbioscience.com
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p53 compared to p53 null or p53 mutant expressing tumor cells.
This increased localization of 64Cu in the nuclei may cause increased
DNA damage to cells, and therefore improved tumor cell killing. In
addition, we have identified a role for p53 in the transport of copper
into the cell nucleus.

Materials and Methods

Figure 2. Saturation receptor binding of 64Cu‑DOTA‑cetuximab to cell
membranes isolated from HCT 116 cell lines positive (£) and negative (p)
for p53. Dissociation constants (Kd, 0.95 ± 0.26 nM vs. 1.13 ± 0.22 nM)
and maximum receptor densities (Bmax, 1,950 ± 180 fmol/mg vs. 2,180 ±
150 fmol/mg) were similar for HCT 116 +/+ and HCT 116 ‑/‑ cell lines,
respectively (N = 3).

DNA damage, hypoxia, chromosomal aberrations, telomere short‑
ening and others, whereupon it accumulates in the nucleus,41 acting
as a sequence‑specific transcriptional regulator. Copper toxicity is
correlated with apoptotic cell death, and translocation of p53 from
the cytosol into the nucleus has been shown to occur in cells treated
with 200 mM copper supplied as cupric sulfate.42 Our study shows
that presence of p53 in turn increases the amount of 64Cu that is
transported to the nucleus of HCT 116 cells. Copper is capable of
displacing zinc from metal‑binding sites in proteins and has been
shown to bind to p53 in vitro.19 Thus one possibility is that p53
itself is responsible for the increased transport of 64Cu into the nuclei
of HCT 116+/+ cells. We are currently examining another option,
namely that one of the many binding partners of p53 complexes
64Cu and is transported to the nucleus together with p53. One
promising candidate is metallothionein, which is involved in the
intracellular storage of metal ions like zinc and copper, and which
has been shown to physically interact with p53 by co-immunopre‑
cipitation with both anti‑p53 and anti‑metallothionein antibodies.43
A third potential mechanism involves proteins from genes whose
expression is upregulated by p53 after exposure to the radiocopper.
Oligonucleotide array studies in neurons identified several p53 target
genes which are differentially regulated after exposure to copper.44
Genes involved in cell cycle arrest (e.g., p21, reprimo, stathmin,
Tp53INP1) and apoptotic processes (e.g., IGFBP‑6, PUMA), as
well as heat‑shock proteins (e.g., Hsp70, Hsp 27) were identified;
however, their potential role in copper transport has not yet been
examined. Finally, it is possible that HCT 116+/+ cells express a
protein spectrum fundamentally different from HCT 116‑/‑ cells in
quality and quantity even in the ground state before exposed to any
external stressor like radiation. This implies that the transcription of
an as of now unknown copper‑binding protein would be activated
by basal levels of p53.
In summary, the data presented here demonstrate a potential
mechanism for increased toxicity of 64Cu radiopharmaceuticals for
targeted radiotherapy of cancer involving the tumor suppressor
protein p53. Copper‑64 radiopharmaceuticals may show enhanced
localization of 64Cu in tumor cell nuclei in tumors that express WT
66

Materials. 1,4,7,10‑Tetraazacyclododecane‑1,4,7‑tris(t‑bu
tyl acetate)‑10‑acetic acid mono (N‑hydroxysuccinimide ester)
[DOTA‑mono‑NHS‑tris(tBu) ester] was purchased from Macrocyclics
(Dallas, TX). Centricon 100 concentrators were purchased from
Amicon Inc. (Beverly, MA). All chemicals used were purchased
from Aldrich Chemical Co. (Milwaukee, WI). All solutions were
made using distilled deionized water (Milli‑Q; ~18 MW resistivity).
Monoclonal antibody cetuximab (C225) was kindly provided by
ImClone Systems (New York, NY). HCT 116 +/+ and HCT 116
‑/‑ cell lines were kindly provided by Dr. Bert Vogelstein (Johns
Hopkins University). A Branson Sonifier cell disrupter, and a Sorvall
RC2‑B centrifuge were used in the receptor binding experiments.
Size‑exclusion HPLC used in conjugation and purification of radio‑
labeled conjugate was accomplished on a Superose 12 HR 10/300
column (Amersham Biosciences, Uppsala, Sweden) with a Waters
(Milford, MA) 2487 dual l absorbance detector and an Ortec Model
661 (EG&G Instruments, Oak Ridge, TN) radioactive detector.
The mobile phase was 20 mM HEPES, 150 mM NaCl, pH 7.3
eluted at a flow rate of 0.5 ml/min. Millenium 32 software (Waters,
Milford, MA) was used to quantify chromatograms by integration.
A Beckman 8000 automated well‑typed gamma counter (Fullerton,
CA) was used to measure internalization and nuclear uptake samples.
Copper‑64 was produced as previously reported on a biomedical
cyclotron CS‑15 at Washington University School of Medicine.28
Preparation of 64Cu‑DOTA‑cetuximab. DOTA was conjugated
to cetuximab in 0.1 M Na2HPO4 (pH 7.5) using an adaptation of
the method described by Lewis et al.29 Cetuximab (2 mg/ml) was
washed with 0.1 M Na2HPO4 (pH 7.5) and concentrated using a
Centricon 100. DOTA‑mono‑NHS‑tris(tBu) ester was dissolved in
0.1 M Na2HPO4 (pH 7.4) and pH was adjusted to 7.4 by adding
0.1 M NaOH. An aliquot of this solution was added to the concen‑
trated cetuximab in a molar ratio of DOTA‑mono‑NHS‑tris(tBu)
ester : cetuximab = 90 : 1, followed by incubation at 4°C overnight
with end‑over‑end rotation. The conjugate was then transferred to
a Centricon 100, diluted to 2.0 ml with 0.1 M ammonium citrate
(pH 5.5), and centrifuged. This procedure was repeated to remove
small molecule reactants and the conjugate was collected from the
membrane. Purity and concentration of the resulting conjugate were
determined by size‑exclusion HPLC, and DOTA‑cetuximab was
stored at 4°C until needed.
Radiolabeling of DOTA‑cetuximab with 64Cu was carried out
by adding approximately 100 mg of the conjugate to 0.5–2 mCi
(19 –74 MBq) 64CuCl2 in 0.1 M ammonium citrate buffer, pH 5.5,
followed by a 1 h incubation at 40°C. The radiochemical purity of
the resulting 64Cu‑DOTA‑cetuximab was determined by size‑exclu‑
sion HPLC and radio‑TLC. If necessary, 64Cu‑DOTA‑cetuximab
was challenged with 5 ml of 10 mM EDTA to complex free 64Cu.
64Cu‑DOTA‑cetuximab was then isolated with a ZebaTM Desalt
Spin column (0.5 ml, Pierce, Rockford, IL) to obtain radiochemical
purities > 95%.
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bound activity was measured with a 1450 Microbeta
liquid scintillation and luminescence counter (Perkin
Elmer, Boston, MA). Specific binding was obtained by
subtraction of non-specific binding from total binding.
Maximum binding capacities (Bmax) were estimated
from non-linear curve fitting of specific binding
versus the concentration of 64Cu‑DOTA‑cetuximab
using GraphPad Prism (San Diego, CA).
Internalization and efflux of [64Cu]copper acetate
and 64Cu‑DOTA‑cetuximab in HCT 116 cell lines.
HCT 116 +/+ or HCT 116 ‑/‑ cells were seeded in
6‑well plates containing growth medium (McCoy’s 5a
medium with 1.5 mM L‑glutamine adjusted to contain
2.2 g/l sodium bicarbonate, 90%; fetal bovine serum,
Figure 3. (A) %ID/mg of 64Cu‑DOTA‑cetuximab internalized in HCT 116 cell lines positive 10%) and were incubated at 37°C, 5% CO until 80%
2
(£) and negative (p) for p53. (B) Percentage of internalized activity localized to the nuclear
confluent. On the day of the assay, the medium was
64
fraction of HCT 116 cells per mg (N = 6 with two independent Cu productions).
aspirated and 3 ml fresh growth medium was placed in
each well. For determination of nonspecific internal‑
ization in the cetuximab experiments, one set of wells
was incubated with unlabeled cetuximab (375 mg/100 ml) at 37°C,
5% CO2 for 10 min to block EGF receptors. [64Cu]copper acetate
(25 mCi/10 ml) or 64Cu‑DOTA‑cetuximab (3.6 mCi, 0.38 mg/15
ml) were added to all of the wells and incubated at 37°C, 5% CO2
for 1, 4 or 24 h. At each time point, radioactive medium was aspi‑
rated, and the plate was washed twice with 2 ml PBS. To collect
the surface‑bound fraction, each well was treated with 20 mM
sodium acetate in PBS (pH 3.0) and was incubated at 4°C for 10
min followed by a second 20 mM sodium acetate in PBS (pH 3.0)
wash without incubation, which was pooled with the first rinse.
The cellular fraction was solubilized in 0.1% SDS. All of the frac‑
tions were counted for radioactivity with a gamma counter. The
percentage internalized was the amount of activity in the final cell
pellet, corrected for activity in the blocked fractions and background
activity, and normalized to protein content.
For efflux experiments, cells were seeded in 6‑well plates and
allowed to adhere overnight. Cells were fed 3 ml fresh growth media
Figure 4. Efflux of 64Cu‑DOTA‑cetuximab from HCT 116 cell lines positive on the morning of the experiment, 64Cu‑DOTA‑cetuximab was
(£) and negative (p) for p53. Efflux is expressed as the percentage of
added to each well, and cells were incubated at 37°C, 5% CO2 for
retained activity, where the activity at t = 0 (when the radioactive media is
4 h. The radioactive medium was removed and the cells were washed
removed) is 100%.
twice with ice cold PBS. Fresh growth medium (3 ml) was added to
each well, and the cells were incubated for 1, 4 or 20 h. At each time
Binding affinity of 64Cu‑DOTA‑cetuximab. Cell membranes point, the media was removed and the cells were washed twice with
from HCT 116+/+ and HCT 116‑/‑ cell lines for binding assays ice cold PBS. The cells were solubilized in 0.1% SDS, transferred
were prepared as previously described.30 Assays were performed on a to a microfuge tube, and counted for radioactivity on the gamma
96‑well Multiscreen® Durapore filtration plate (Millipore, Billerica, counter.
Nuclear localization of [64Cu]copper acetate and 64Cu‑DOTA‑
MA) using methods previously described with some modifications.31
Membranes were diluted in binding buffer (50 mM Tris‑HCl, cetuximab in HCT 116 cell lines. For isolation of HCT 116 cell
pH 7.4, 5 mM MgCl2 · 6 H2O, 0.1% BSA, 0.5 mg/ml aprotinin, nuclei, the procedure of Wang et al.14 was used. The experiments
200 mg/ml bacitracin, 10 mg/ml leupeptin, and 10 mg/ml pepstatin were performed in T‑175 flasks containing approximately 5 x 107
A), and 10 mg of membrane protein were used per well. Increasing cells at the beginning of the time course. 64Cu‑DOTA‑cetuximab
concentrations (0.05 nM–6 nM) of 64Cu‑DOTA‑cetuximab were (4.0 mCi, 0.33 mg/20 ml) was added, and after incubation times
added to membranes to measure total binding, and non-specific of 1, 4 and 24 h, the cells were pelleted and resuspended in CSK
binding was determined by conducting the assay in the presence of buffer (0.5% Triton X‑100, 300 mM sucrose, 100 mM NaCl, 1 mM
an excess (2 mM) of cetuximab. After incubation at RT for 2 h, the EGTA, 2 mM MgCl2 and 10 mM PIPES, pH 6.8) and incubated
medium was removed with a vacuum manifold and the membranes on ice for 2 min. Cell lysates were centrifuged at 560 g for 5 min at
were washed twice with 200 ml binding buffer. OptiPhase ‘Super‑Mix’ 4°C, and the supernatant was discarded. The nuclear pellet was resus‑
(PerkinElmer, Boston, MA) (25 ml) was added to each well, and pended in 1 ml CSK buffer without Triton X‑100, and centrifuged
www.landesbioscience.com
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at 560 g at 4°C for 5 min. The supernatant was discarded and the
nuclear pellet was counted with a gamma counter. Aliquots of nuclei
were assayed qualitatively for purity by fluorescence microscopy after
staining with a 1:10 dilution of FITC (3 mg/ml) and propidium
iodide (7 mg/ml). Micrographs were obtained at 100, 200 and 1000
magnification. The yield of nuclei was determined by counting the
initial cell number and the collected nuclei using a Coulter Counter.
The percentage in the cell nucleus was determined by the gamma
counts in the pure nucleus divided by gamma counts internalized
into whole cells, and was corrected for the yield of nuclei.
As an additional control in the HCT 116 cell lines, nuclear
uptake of [64Cu]copper acetate was determined in HCT 116+/+
cells after downregulation of p53 by p53 siRNA, and compared
to untreated HCT 116+/+ and HCT 116‑/‑ cells. Cells were seeded
in T‑75 flasks so that they were 30–40% confluent after 24 h.
TransPassTM R1 Transfection Reagent (200 ml; New England
BioLabs, Boston, MA) was mixed with 5 ml serum‑free medium
and incubated for 15 min at RT. p53 ShortCut® siRNA Mix
(20 ml; New England BioLabs) was added, followed by another 15
min incubation at RT and addition of 43 ml medium with serum.
This mixture was added to HCT 116+/+ cells (12 ml/flask) and the
cells were grown for 48 h under standard conditions. A change to
fresh medium was followed by additional 24 h of incubation, and
nuclear localization experiments were then conducted as described
above.
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